NCT06134193View on ClinicalTrials.gov

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
CarcinomaIntrahepatic CholangiocarcinomaGallbladder CancerSurufatinibAngiogenesis InhibitorsTislelizumabAntineoplastic Agents, ImmunologicalImmunotherapy
Interventions
DRUG

HAIC

hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.

DRUG

Surufatinib

250mg PO d1, Q3W

DRUG

Tislelizumab

200mg IV d1, Q3W

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06134193 - Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | Biotech Hunter | Biotech Hunter